Clinical trial · no report yet · Phase 3
IPSOS
A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy
- NCT03191786 ↗
- Completed
- Hoffmann-La Roche
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 21 | |
| YouTube | 10 | |
| Podcasts | 4 | |
| Bluesky threads | 1 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab Compared With Chemotherapy in Patients With Treatment Naïve Advanced or Recurrent (Stage IIIb Not Amenable for Multimodality Treatment) or Metastatic (Stage IV) Non-Small Cell Lung Cancer Who Are Deemed Unsuitable for Platinum-Containing Therapy
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Vinorelbine; Gemcitabine
- Arms
- Atezolizumab · Experimental
- Single Agent Chemotherapy (Vinorelbine or Gemcitabine) · Active comparator
- Enrollment
- 453
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Hoffmann-La Roche
- Start
- Sep 11, 2017
- Primary completion
- Apr 30, 2022
- Results posted
- Yes
- Registry record
- NCT03191786 · updated Oct 23, 2024
Publications
linked from the registry- Han B, Peters S, Le AT, Huang D, Wu G, Cao L, Pham CP, Zhao J, Wang K, Yang N, Zhong H, Hu Y, Morris S, Lam V, Graupner V, Gitlitz B, Hoglander E, Schulz C, Lee SM. First-line atezolizumab monotherapy vs . single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation. Chin Med J (Engl). 2026 Jun 20;139(12):1838-1845. doi: 10.1097/CM9.0000000000003796. Epub 2025 Dec 17. PubMed 41424028
- Peters S, Schulz C, Reck M, Prabhash K, Kowalski D, Szczesna A, Han B, Rittmeyer A, Talbot T, Vicente D, Califano R, Cortinovis D, Le AT, Huang D, Liu G, Cappuzzo F, Contreras JR, Palmero R, Mak MP, Popat S, Hu Y, Morris S, Srivastava MK, Kaul M, Graupner V, Gitlitz B, Lee SM. Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study. J Thorac Oncol. 2025 Dec;20(12):1843-1850. doi: 10.1016/j.jtho.2025.07.115. Epub 2025 Jul 22. PubMed 40706710
- Li B, Rong D, Lin H. Atezolizumab monotherapy as first-line treatment for non-small cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a cost-effectiveness analysis in the USA. BMJ Open. 2024 Nov 12;14(11):e083716. doi: 10.1136/bmjopen-2023-083716. PubMed 39532375
- Lee SM, Schulz C, Prabhash K, Kowalski D, Szczesna A, Han B, Rittmeyer A, Talbot T, Vicente D, Califano R, Cortinovis D, Le AT, Huang D, Liu G, Cappuzzo F, Reyes Contreras J, Reck M, Palmero R, Mak MP, Hu Y, Morris S, Hoglander E, Connors M, Biggane AM, Vollan HK, Peters S. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study. Lancet. 2023 Aug 5;402(10400):451-463. doi: 10.1016/S0140-6736(23)00774-2. Epub 2023 Jul 6. PubMed 37423228
- Gijtenbeek RG, de Jong K, Venmans BJ, van Vollenhoven FH, Ten Brinke A, Van der Wekken AJ, van Geffen WH. Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. Cochrane Database Syst Rev. 2023 Jul 7;7(7):CD013382. doi: 10.1002/14651858.CD013382.pub2. PubMed 37419867